Table 3.
Management of antiretroviral therapy (ART) prior to and during interferon- and ribavirin-free direct-acting antiviral agent (DAA) therapy.
| Antiretroviral treatment (%, n/all) | All patients (n = 38) |
|---|---|
| PI | 3% (1/38) |
| N(t)RTI | 97% (37/38) |
| NNRTI | 21% (8/38) |
| INSTI/EI | 76% (29/38) |
| ART switch prior to DAA initiation | 18% (7/38) |
| discontinuation of (%, n/all) | |
| PI | 3% (1/38) |
| N(t)RTI | 0% (0/38) |
| NNRTI | 16% (6/38) |
| INSTI/EI | 0% (0/38) |
| Need for ART switch according to DAA regimen | |
| SOF/LDV (n = 5) | 0% (0/5) |
| 3D (n = 16) | 25% (4/16) |
| 2D (n = 2) | 50% (1/2) |
| GZV/EBV (n = 2) | 0% (0/2) |
| SOF/VEL (n = 2) | 50% (1/2) |
| G/P (n = 11) | 9% (1/11) |
2D: ritonavir-boosted ombitasvir plus paritaprevir; 3D: ritonavir-boosted ombitasvir plus paritaprevir plus dasabuvir; ART: antiretroviral therapy; DAA: direct-acting antiviral agent; EBV: elbasvir; EI: entry inhibitors; G/P: glecaprevir plus pibrentasvir; GZV: grazoprevir; INSTI: integrase inhibitor; LDV: ledipasvir; NNRTI: non-nucleoside reverse-transcriptase inhibitors; N(t)RTIs: nucleos(t)idic reverse transcriptase inhibitors; PI: protease inhibitor; SOF: sofosbuvir; VEL: velpatasvir.